03:35 PM EST - Trimel Pharmaceuticals Corporation : announced that the United States Food and Drug Administration has decided to extend the Prescription Drug User Fee Act (PDUFA) target action date for the CompleoTRT™ new drug application from February 28 to May 28. This will provide the FDA with the required time for a full review of the submission in light of the previously announced decision by the Company to amend its proposed label. Trimel Pharmaceuticals Corporation
shares T.TRL are trading down $0.15 at $0.66.
